Combination Therapy of Diane-35 and Cangfu Daotan Wan for PCOS Management

### Combination Therapy of Diane-35 and Cangfu Daotan Wan for PCOS Management

**Abstract**: Recent research has demonstrated that the combination of Diane-35, a widely used contraceptive pill, and Cangfu Daotan Wan, a traditional Chinese medicine formula, significantly improves clinical outcomes in patients with Polycystic Ovary Syndrome (PCOS). This study aims to explore the efficacy of this combined therapy in ameliorating inflammatory responses, stress levels, and hormonal imbalances typically associated with PCOS.

**Introduction**: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting approximately 5% to 20% of women of reproductive age worldwide. Characterized by irregular menstruation, hyperandrogenism, and polycystic ovarian morphology, PCOS poses significant long-term health risks, including increased susceptibility to type 2 diabetes and endometrial cancer. Current treatments primarily focus on hormonal regulation and symptom management, with Diane-35 being a first-line medication. However, its long-term use may lead to metabolic side effects. Cangfu Daotan Wan, a traditional Chinese herbal formula, has gained attention for its potential benefits in addressing PCOS symptoms by targeting underlying pathophysiological mechanisms.

**Methodology**: A retrospective study was conducted involving 120 female patients diagnosed with PCOS, who were treated at Taizhou Hospital of Traditional Chinese Medicine between January 2022 and March 2024. Participants were split into two groups: one receiving Diane-35 alone and the other receiving a combination of Diane-35 and Cangfu Daotan Wan. Clinical efficacy was assessed through gynecological ultrasound, hormone level measurements, and inflammatory markers, as well as traditional Chinese medicine symptom scoring.

**Results**: The results demonstrated that patients receiving the combined therapy exhibited a significantly lower incidence of polycystic ovarian changes and an overall treatment efficacy rate of 95%, compared to 61.67% in the control group (p < 0.05). Additionally, levels of inflammatory markers such as IL-6 and TNF-α were significantly reduced in the combination therapy group, indicating a marked anti-inflammatory effect. Improvements in stress response indicators were also noted, with enhanced levels of superoxide dismutase (SOD) and reduced glutathione (GSS) levels observed post-treatment.

**Discussion**: The combination of Diane-35 and Cangfu Daotan Wan appears to synergistically enhance therapeutic effects by targeting both hormonal imbalances and the inflammatory pathways implicated in PCOS. The dual approach addresses the limitations associated with monotherapy, particularly in managing metabolic and psychological symptoms. Moreover, the findings align with the principles of integrated traditional and Western medicine, advocating for a holistic approach to PCOS management.

**Conclusion**: This study provides robust evidence supporting the efficacy of combining Diane-35 with Cangfu Daotan Wan in the comprehensive management of PCOS. Future research should aim to expand sample sizes and explore long-term outcomes, including quality of life assessments, to further validate these findings. The advantages of this integrative treatment approach could pave the way for more effective and safer management strategies for PCOS.

**Keywords**: Polycystic Ovary Syndrome, Diane-35, Cangfu Daotan Wan, Inflammation, Hormonal Regulation, Traditional Chinese Medicine.